Trials / Unknown
UnknownNCT03835949
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
A Phase 1 Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Tracon Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TJ004309 | Antibody to CD73 |
| DRUG | Atezolizumab | Humanized monoclonal antibody to PD-L1 |
Timeline
- Start date
- 2019-07-16
- Primary completion
- 2022-06-01
- Completion
- 2022-06-01
- First posted
- 2019-02-11
- Last updated
- 2022-04-01
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03835949. Inclusion in this directory is not an endorsement.